Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Aisling Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Aisling Capital

Aisling Capital

Operating

Aisling Capital: Investing in healthcare innovations for disease diagnosis, prevention, and treatment.

Location
New York City, NY, US
Founded
2000
Firm
Compare
Portfolio
Employees
Website

Investments

Bicara Therapeutics
Bicara Therapeutics

Total Raised

$313M

Rounds

3

Series C$165MDecember 2023
Garuda Therapeutics
Garuda Therapeutics

Total Raised

$134M

Rounds

2

Series B$62MFebruary 2023
Series A$72MSeptember 2021
Forge Biologics
Forge Biologics

Total Raised

$330M

Rounds

5

Series C$90MSeptember 2022
Dren Bio
Dren Bio

Total Raised

$130.1M

Rounds

4

Series B$65MJune 2022
Antios Therapeutics
Antios Therapeutics
Public

Total Raised

$200.4M

Rounds

4

Series B$75MNovember 2021
Series B$96MApril 2021
Wugen
Wugen

Total Raised

$172M

Rounds

2

Series B$172MJuly 2021
Spruce Biosciences
Spruce Biosciences
Public

Total Raised

$161.6M

Rounds

4

Series B$88MFebruary 2020
Ajax Health
Ajax Health

Total Raised

$315M

Rounds

4

Series C$15MJune 2019
Series C$85MApril 2019
Series B$120MJuly 2018
Series A$95MJanuary 2017
Poseida Therapeutics
Poseida Therapeutics
Public

Total Raised

$460.5M

Rounds

10

Series C$142MApril 2019
BridgeBio Pharma
BridgeBio Pharma
Public

Total Raised

$3.6B

Rounds

13

Series D$299.2MJanuary 2019
Series C$135MSeptember 2017
Earlens
Earlens

Total Raised

$318.8M

Rounds

9

Series D$87MOctober 2018
Series C$73MJune 2017
Zosano Pharma
Zosano Pharma
Public

Total Raised

$271.9M

Rounds

15

Post Ipo Equity$50MApril 2018
Arcus Biosciences
Arcus Biosciences
Public

Total Raised

$967M

Rounds

7

Series C$107MNovember 2017
Vyne Therapeutics
Vyne Therapeutics
Public

Total Raised

$297.8M

Rounds

7

Series C$50.5MJuly 2017
Promentis Pharmaceuticals
Promentis Pharmaceuticals

Total Raised

$63.9M

Rounds

9

Series C$26MMarch 2017
Bristol Myers Squibb
Bristol Myers Squibb
Public

Total Raised

$10.6B

Rounds

4

Post Ipo Equity$80MFebruary 2017
Prolacta Bioscience
Prolacta Bioscience

Total Raised

$78M

Rounds

8

Series Unknown$35MDecember 2016
Biohaven
Biohaven
Acquired

Total Raised

$755.6M

Rounds

8

Series Unknown$80MNovember 2016